Assessment of lncRNA GAS5, lncRNA HEIH, lncRNA BISPR and its mRNA BST2 as serum innovative non-invasive biomarkers: Recent insights into Egyptian patients with hepatitis C virus type 4

Table 4 Factors that predict response to SOF + SIM (n = 30), SOF + DAC (n = 20) or SOF + DAC + RBV (n = 20) treatment regimens using logistic regression analysis

Paramete	B	SE	P value	Odds ratio	Odds ratio (95%CI)
Univariate analysis (SOF + SIM)
LncRNA-Gas5	2.135	0.583	< 0.001c	8.45	2.69-26.50
LncRNA-BISPR	1.733	0.482	< 0.001c	5.65	2.19-14.56
mRNA BST2	-2.029	0.501	< 0.001c	0.13	0.04-0.351
ALT (IU/L)	0.084	0.03	0.005b	1.08	1.025-1.153
AFP (ng/mL)	0.715	0.299	0.01a	2.044	1.137-3.675
ALP (IU/L)	0.209	0.067	0.002b	1.232	1.080-1.405
Albumin (mg/dL)	-1.947	0.635	0.002b	0.143	0.041-0.495
Multivariate analysis
LncRNA-Gas5	1.397	0.704	0.04a	4.04	1.01-16.073
LncRNA-BISPR	1.613	820	0.04a	5.01	1.007-25.02
mRNA BST2	-3.149	1.307	0.01a	0.043	0.003-0.556
Univariate analysis (SOF + DAC)
LncRNA-Gas5	1.54	0.48	0.002b	4.69	1.80-12.26
LncRNA-BISPR	1.86	0.61	0.003b	6.43	1.91-21.59
mRNA BST2	-1.677	0.415	< 0.001c	0.187	0.083-0.422
ALT (IU/L)	0.125	0.048	0.01a	1.13	1.031-1.245
AFP (ng/mL)	0.715	0.299	0.01a	2.044	1.137-3.675
ALP (IU/L)	0.729	0.296	0.01a	2.073	1.161-3.699
Multivariate analysis
LncRNA-Gas5	1.17	0.54	0.03a	3.05	1.06-8.79
LncRNA-BISPR	1.42	0.69	0.03a	4.17	1.07-16.1
Univariate analysis (SOF + DAC + RBV)
LncRNA-Gas5	1.12	0.33	0.001b	3.07	1.6-5.88

^aP < 0.05,

^bP < 0.01, indicates statistical significance. ALT: Alanine aminotransferases; AFP: Alfa fetoprotein; ALP: Alkaline phosphatase.